glp 1 optic nerve The Impact of GLP-1 Receptor Agonists on Ocular Disease The Benefits and Risks of

It has not undergone Phase I, II, or III human clinical trials and is not recognized as Generally Recognized as Safe (GRAS)

Reported mechanisms should be read as hypotheses from laboratory and animal data

In contrast, after the addition of SB431542, a TGF signalling inhibitor, to the high-glucose medium, -SMA expression in PSCs decreased to a nearly undetectable level

Beyond Novo and Eli Lilly, companies such as Boehringer Ingelhium, Pfizer, Roche, AstraZeneca, Regor therapeutics, Viking Therapeutics, Amgen, BioAge Labs, Gan & Lee Pharmaceuticals, Sun Pharma, Innovent Biologics, Aphaia Pharma, Vertex Pharmaceuticals , and others are entering the space, fueling new innovations in GLP-1 therapies, combination therapies, and next-gen metabolic treatments